Press release
Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Curious about the latest updates in the Liver Fibrosis Pipeline? @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight [https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Liver Fibrosis Pipeline Report
* On April 02, 2026- Boehringer Ingelheim initiated a phase II study is to find out the effect of survodutide on MASH and liver fibrosis. The purpose of the second part is to find out how safe and effective survodutide is in improving liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo.
* On April 02, 2026- Beijing Continent Pharmaceutical Co, Ltd . conducted a study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis .
* DelveInsight's Liver Fibrosis Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Liver Fibrosis treatment.
* The leading Liver Fibrosis Companies such as Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others.
* Promising Liver Fibrosis Therapies such as Candesartan, Ramipril, Hydronidone, Atorvastatin 20mg, Silymarin, Ursodeoxycholic Acid, ND-L02-s0201 Injection, Sildenafil 20 MG, Sulfasalazine enteric-coated tablets and others.
Want to know which companies are leading innovation in Liver Fibrosis? Dive into the full pipeline insights @ Liver Fibrosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Liver Fibrosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Liver Fibrosis Pipeline Report also highlights the unmet needs with respect to the Liver Fibrosis.
Liver Fibrosis Overview
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver due to chronic injury. It is a progressive condition that results from sustained inflammation and hepatocyte damage, often caused by chronic viral hepatitis (HBV, HCV), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), or autoimmune liver diseases. While early-stage fibrosis may be reversible, advanced fibrosis can progress to cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
Liver Fibrosis Emerging Drugs Profile
* Aramchol: Galmed Research and Development, Ltd
Aramchol (Arachidyl Amido Cholanoic Acid) is a first-in-class, novel synthetic small molecule, a conjugate of Cholic Acid and Arachidic Acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (Nonalcoholic Steatohepatitis) and fibrosis. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation, and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol, by targeting this single receptor, induces a cascade of events that leads to two main changes; in hepatocytes, Aramchol elevates the fatty acids oxidation (or in other words - fat burn) and influences AMPK, which results also in reducing glycemic parameters; and in hepatic stellate cells, Aramchol has been shown to down-regulate the expression and activity of stearoyl-CoA desaturase-1 (SCD-1), resulting in a direct effect on fibrogenesis. Currently, the drug is in the Phase III stage of its development for the treatment of Liver Fibrosis
* Belapectin: Galectin Therapeutics
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. Currently, the drug is in Phase II/III stage of development for the treatment of liver fibrosis.
* AZD2693: AstraZeneca
AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA. AZD2693 lowers the mRNA expression of PNPLA3 in patients that are homozygotes for the 148M risk allele thereby reducing an important disease driver for NASH. AZD2693 has been evaluated in 3-month repeat dose subcutaneous toxicity study in preclinical species. Findings were consistent with typical class effects of ASOs, including histiocytic infiltration in multiple tissues and evidence of ASO accumulation in liver and spleen. No effects were attributed to the reduction in PNPLA3. Preclinical safety pharmacology studies have also been conducted with no effects on the respiratory, cardiovascular, and central and peripheral nervous systems. Under preclinical pharmacology, Murine PNPLA3 tool ASO has been shown to reduce liver steatosis, inflammation and fibrosis in homozygous PNPLA3 148M knock-in mice. Currently, the drug is in the Phase II stage of its development for the treatment of Liver Fibrosis.
* RTX001: Resolution Therapeutics
RTX001 is an engineered, autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effect. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is an innovative medical treatment being studied for patients with decompensated liver cirrhosis. It is classified as an autologous macrophage therapy, which means it uses the patient's own immune cells to potentially treat their condition. RTX001 is administered as a dispersion for infusion, which is a liquid form of the medication that is given directly into the bloodstream through an Intravenous (IV) line. Currently, the drug is in the Phase I/II stage of its development for the treatment of Liver Fibrosis
* AD-214: AdAlta
AD-214 is AdAlta's lead drug candidate, an Fc-fusion protein that combines anti-body with the Fc fragment of a traditional monoclonal antibody to extend its duration in the body. AD-214 binds to the CXCR4 receptor on target diseased cells, exerting anti-inflammatory and anti-fibrotic effects without impacting healthy cells. It has demonstrated efficacy in animal models of fibrosis and is being explored for the treatment of liver fibrosis. Currently, the drug is in Preclinical stage of its clinical trial for the treatment of liver fibrosis.
If you're tracking ongoing Liver Fibrosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Liver Fibrosis Treatment Drugs [https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Liver Fibrosis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Liver Fibrosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Fibrosis Treatment.
* Liver Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Liver Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Fibrosis market.
Liver Fibrosis Companies
Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others.
Liver Fibrosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Liver Fibrosis Products have been categorized under various Molecule types such as,
* Monoclonal antibody
* Small molecule
* Peptide
From emerging drug candidates to competitive intelligence, the Liver Fibrosis Pipeline Report covers it all - check it out now @ Liver Fibrosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Liver Fibrosis Pipeline Report
* Coverage- Global
* Liver Fibrosis Companies- Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others
* Liver Fibrosis Therapies- Candesartan, Ramipril, Hydronidone, Atorvastatin 20mg, Silymarin, Ursodeoxycholic Acid, ND-L02-s0201 Injection, Sildenafil 20 MG, Sulfasalazine enteric-coated tablets and others.
* Liver Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Liver Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Liver Fibrosis Treatment landscape in this detailed analysis @ Liver Fibrosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Introduction
2. Executive Summary
3. Liver Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Fibrosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Aramchol: Galmed Research and Development, Ltd
9. Mid Stage Products (Phase II)
10. Belapectin: Galectin Therapeutics
11. Early Stage Products (Phase I)
12. RTX001: Resolution Therapeutics
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Liver Fibrosis Key Companies
16. Liver Fibrosis Key Products
17. Liver Fibrosis- Unmet Needs
18. Liver Fibrosis- Market Drivers and Barriers
19. Liver Fibrosis- Future Perspectives and Conclusion
20. Liver Fibrosis Analyst Views
21. Liver Fibrosis Key Companies
22. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-fibrosis-clinical-trial-pipeline-accelerates-as-50-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/liver-fibrosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight here
News-ID: 4457094 • Views: …
More Releases from ABNewswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and ex …
Key Prader-Willi Syndrome Companies are Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Prader-Willi…
From Factory Floor to the C-Suite: Mohsine "Mo" Gdid's Heart of the Line Redefin …
A new voice in leadership is emerging, one shaped not in boardrooms, but on the production line.
In Heart of the Line: [https://a.co/d/04lPMGIu] From Factory Floor to the C-Suite, Mohsine "Mo" Gdid shares a powerful and deeply personal journey that challenges conventional ideas of leadership. Drawing from his experience starting on a factory floor and rising into executive leadership, Gdid offers a perspective grounded in real work, real people, and real…
Miami Wage and Hour Attorney Jason D. Berkowitz Details FLSA Exemption Categorie …
MIAMI, FL - Employers who incorrectly classify workers as exempt from overtime protections under the Fair Labor Standards Act may owe years of back wages and liquidated damages, yet misclassification remains widespread across industries in South Florida. Miami wage and hour attorney Jason D. Berkowitz of BT Law Group, PLLC (https://btattorneys.com/flsa-exemption/) is explaining the three primary FLSA exemption categories, how misclassification occurs, and what remedies are available to workers who…
Opioid Use Disorder Clinical Trial Pipeline Appears Robust With 10+ Key Pharma C …
DelveInsight's "Opioid Use Disorder Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Opioid Use Disorder pipeline landscape. It covers the Opioid Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Opioid Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
